{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:40:35Z","timestamp":1793644835389,"version":"4.5.1"},"reference-count":68,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Biologicals SA was involved in all stages of the conduct and analysis of the studies and covered the costs associated with the development and the publishing of the present manuscript"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2021,9,2]]},"DOI":"10.1080\/14760584.2021.1956906","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T07:16:17Z","timestamp":1627370177000},"page":"1065-1075","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":49,"title":["A practitioner\u2019s guide to the recombinant zoster vaccine: review of national vaccination recommendations"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8412-307X","authenticated-orcid":false,"given":"Raunak","family":"Parikh","sequence":"first","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Widenmaier","sequence":"additional","affiliation":[{"name":"GSK, Rockville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Lecrenier","sequence":"additional","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a3516e"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268817001546"},{"issue":"5","key":"cit0004","first-page":"1","volume":"57","author":"Harpaz R","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-011-0162-0"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2911"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.10.009"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3719-7"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.046"},{"key":"cit0011","unstructured":"European Centre for Disease Prevention and Control. Vaccine schedules in all countries of the European Union; [cited 2020 Apr 21]. Available from: https:\/\/vaccine-schedule.ecdc.europa.eu"},{"key":"cit0012","unstructured":"World Health Organization. WHO vaccine-preventable diseases: monitoring system; 2020 Global summary [cited 2020 Nov 21]. Available from: https:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/schedules"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir970"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis638"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu918"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(17)30234-7"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001420"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw047"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwx245"},{"key":"cit0020","unstructured":"Zostavax (package insert): food and drug administration; [cited 2020 Apr 23]. Available from: https:\/\/www.fda.gov\/media\/82524\/download"},{"key":"cit0021","unstructured":"Summary of product characteristics: Zostavax: European Medicines Agency; 2020 [cited 2021 Apr 23]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zostavax-epar-product-information_en.pdf"},{"key":"cit0022","unstructured":"Product monograph: ZOSTAVAX\u00ae II Merck Canada Inc. 2017 [cited 2020 Apr 21]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00042265.PDF"},{"key":"cit0023","unstructured":"Product monograph: SHINGRIX: GlaxoSmithKline Inc. 2017 [cited 2020 Apr 21]. Available from: https:\/\/ca.gsk.com\/media\/1350788\/shingrix_pm-2017-10-13.pdf"},{"key":"cit0024","unstructured":"Shingrix (package insert): Food and Drug Administration. 2018 [cited 2020 Apr 22]. Available from: https:\/\/www.fda.gov\/media\/108597\/download"},{"key":"cit0025","unstructured":"Summary of product characteristics: Shingrix: European Medicines Agency. 2020 [updated 2020 Sep 28;cited 2020 Oct 2]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/shingrix-epar-product-information_en.pdf"},{"key":"cit0026","unstructured":"Report on the deliberation results: Pharmaceuticals and Medical Devices Agency (Japan); 2018 [cited 2020 Apr 29]. Available from: https:\/\/www.pmda.go.jp\/files\/000233792.pdf#page=2"},{"key":"cit0027","unstructured":"Australian public assessment report for recombinant Varicella Zoster Virus (VZV) glycoprotein E (gE) antigen: therapeutic Goods Administration (Australia); 2018 [cited 2020 Apr 28]. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-recombinant-varicella-zoster-virus-glycoprotein-e-antigen-181212.pdf"},{"key":"cit0028","unstructured":"GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over: GSK; 2019 [cited 2020 May 03]. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-announces-approval-of-shingrix-in-china-for-prevention-of-shingles-in-adults-aged-50-and-over"},{"key":"cit0029","unstructured":"Shingrix (Recombinant Varicella Zoster Virus Vaccine) Risk Management Plan Medicines Adverse Reactions Committee (New Zealand); 2019 [cited 2020 Apr 23]. Available from: https:\/\/medsafe.govt.nz\/committees\/MARC\/reports\/179-3.2.4ShingrixRMP.pdf"},{"key":"cit0030","unstructured":"Hong Kong Drug Office. List of registered pharmaceutical products; [cited 2021 Jan 05]. Available from: https:\/\/www.drugoffice.gov.hk\/eps\/do\/en\/consumer\/news_informations\/reListRPP.html?srtRange=SA&ndRange=SZ"},{"key":"cit0031","unstructured":"Health Sciences Authority. New drug approvals; Jan 2021 [cited 2021 May 14]. Available from: https:\/\/www.hsa.gov.sg\/announcements\/new-drug-approval\/new-drug-approvals\u2014jan-2021"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603800"},{"key":"cit0034","volume":"50","author":"Standing Committee on Vaccination (STIKO)","year":"2018","journal-title":"Epi Bull"},{"key":"cit0035","first-page":"313","volume":"34","author":"Standing Committee on Vaccination (STIKO)","year":"2019","journal-title":"Epi Bull"},{"key":"cit0036","unstructured":"Health Council of the Netherlands. Vaccination against shingles 2019; [cited 2020 Apr 22]. Available from: https:\/\/www.healthcouncil.nl\/documents\/advisory-reports\/2019\/07\/15\/vaccination-of-older-people-against-shingles"},{"key":"cit0037","unstructured":"Bundesministerium f\u00fcr Arbeit, Soziales, Gesundheit und Konsumentenschutz (BMASGK), Nationalen Impfgremiums. Der Impfplan \u00d6sterreich [Austrian vaccination plan]; 2021 [cited 2021 May 14]. Available from: https:\/\/www.sozialministerium.at\/Themen\/Gesundheit\/Impfen\/Impfplan-%C3%96sterreich.html"},{"key":"cit0038","unstructured":"Centers for Disease Control and Prevention. Shingrix recommendations [cited 2021 Jan 05]. Available from: https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/shingrix\/recommendations.html"},{"key":"cit0039","unstructured":"Gobierno de Espa\u00f1a, Ponencia de Programa y Registro de Vacunaciones. Recomendaciones de vacunaci\u00f3n frente a herpes z\u00f3ster [Presentation of the immunization program and records - Vaccination recommendations against herpes zoster]; 2021 [cited 2021 Apr 28]. Available from: https:\/\/www.mscbs.gob.es\/en\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/programasDeVacunacion\/docs\/HerpesZoster_RecomendacionesVacunacion.pdf"},{"key":"cit0040","first-page":"391","volume":"36","author":"Standing Committee on Vaccination (STIKO)","year":"2017","journal-title":"Epi Bull"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6703a5"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7006a2"},{"key":"cit0043","unstructured":"Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older; United States, 2021 [cited 2021 May 14]. Available from: https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/adult.html"},{"key":"cit0044","unstructured":"National Advisory Committee on Immunization (NACI). Updated recommendations on the use of herpes zoster vaccines 2018 [cited 2020 Apr 22]. Available from: https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/healthy-living\/updated-recommendations-use-herpes-zoster-vaccines-eng.pdf"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v44i09a06"},{"key":"cit0046","unstructured":"Joint Committee on Vaccination and Immunisation. Minute of the meeting held on 06 February 2019 2019; [cited 2020 Apr 22]. Available from: https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/file\/424913874479"},{"key":"cit0047","unstructured":"SZU National Institute of Public Health (Czech Republic). O\u010dkovac\u00ed kalend\u00e1\u0159 pro dosp\u011bl\u00e9 - podle v\u011bku [Vaccination calendar for adults - by age]; [cited 2020 Apr 28]. Available from: http:\/\/www.szu.cz\/uploads\/Epidemiologie\/Infekce_zakladni_informace\/2019_Aktualiz_ockovaci_kalendar_dosp_.pdf"},{"key":"cit0048","unstructured":"SZU National Institute of Public Health (Czech Republic). Z\u00e1kladn\u00ed informace o infekc\u00edch v r\u00e1mci o\u010dkov\u00e1n\u00ed v \u010cR I [Basic information on infections within vaccination in the Czech Republic I; [cited 2020 Apr 28]. Available from: http:\/\/www.szu.cz\/tema\/vakciny\/zakladni-informace-o-infekcich-v-ramci-ockovani-v-cr-i"},{"key":"cit0049","unstructured":"National Immunisation Advisory Committee. Immunization guidelines. Chapter 23: varicella-Zoster [updated 2020 Mar; cited 2020 24 Oct]. Available from: https:\/\/www.hse.ie\/eng\/health\/immunisation\/hcpinfo\/guidelines\/chapter23.pdf"},{"key":"cit0050","unstructured":"National Immunisation Advisory Committee. Immunization guidelines. Chapter 3: immunisation of immunocompromised persons; [updated 2020 June; cited 24 Sep 2020]. Available from: https:\/\/www.hse.ie\/eng\/health\/immunisation\/hcpinfo\/guidelines\/chapter3.pdf"},{"key":"cit0051","unstructured":"Ministero della Salute. Aggiornamento sulla vaccinazione contro herpes zoster [Update on herpes zoster vaccination]; 2021 [cited 2021 May 14]. Available from: https:\/\/www.trovanorme.salute.gov.it\/norme\/renderNormsanPdf?anno=2021&codLeg=79080&parte=1%20&serie=null"},{"key":"cit0052","unstructured":"Ministero della Salute. Il calendario vaccinale del Piano Nazionale di Prevenzione Vaccinale 2017-2019 [The vaccination calendar of the National Vaccine Prevention Plan 2017-2019]; 2017 [cited 2021 May 14]. Available from: http:\/\/www.salute.gov.it\/imgs\/C_17_pagineAree_4829_listaFile_itemName_0_file.pdf"},{"key":"cit0053","unstructured":"National Advisory Committee on Immunization (NACI). Update on the use of herpes zoster vaccine; 2014 [cited 2020 Apr 22]. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/update-use-herpes-zoster-vaccine.html."},{"issue":"9","key":"cit0054","first-page":"170","volume":"40","author":"Canadian Immunization Committee","year":"2014","journal-title":"Can communicable dis rep Releve mal transmissibles Can"},{"key":"cit0055","unstructured":"Public Health England. The Green Book: immunisation against infectious disease. Chapter 28a Shingles (herpes zoster) 2016 [cited 2020 Apr 20]. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/503773\/2905109_Green_Book_Chapter_28a_v3_0W.PDF"},{"key":"cit0056","unstructured":"Ezeanolue E, Harriman K, Hunter P, et al. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP) [cited 2020 Apr 23]. Available from: https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/downloads\/general-recs.pdf"},{"key":"cit0057","unstructured":"Herpes zoster (shingles) vaccine: canadian Immunization Guide 2018 [cited 2020 Apr 21]. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-8-herpes-zoster-(shingles)-vaccine.html#a3"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1265715"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix482"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.11.019"},{"key":"cit0061","unstructured":"Robert Koch Institute. Shingles (herpes zoster): answers to frequently asked questions about the disease and vaccination 2020 [cited 2021 May 05]. Available from: https:\/\/www.rki.de\/SharedDocs\/FAQ\/Herpes_zoster\/FAQ-Liste.html;jsessionid=AB656F4D87A7A28ADC7C8F3E643D83BE.internet081"},{"issue":"1","key":"cit0062","first-page":"S417","volume":"4","author":"Vink P","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"cit0063","first-page":"181","volume":"70","author":"Vink P","year":"2020","journal-title":"Clin Infect Dis"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1232787"},{"key":"cit0065","unstructured":"Centers for Disease Control and Prevention. Administering Shingrix [cited 2021 May 05]. Available from: https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/shingrix\/administering-vaccine.html"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix481"},{"key":"cit0067","unstructured":"Immunization of persons with chronic diseases: canadian Immunization Guide; 2018 [cited 2020 Oct 18]. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-3-vaccination-specific-populations\/page-7-immunization-persons-with-chronic-diseases.html"},{"key":"cit0068","unstructured":"Institut National de Sant\u00e9 Publique du Qu\u00e9bec. Vaccination des personnes immunosupprim\u00e9es \u00e2g\u00e9es de 18 \u00e0 49 ans et des adultes avec des maladies chroniques: vaccin sous-unitaire adjuvant\u00e9 contre le zona (Zona-SU) [Vaccination of immunocompromised persons aged 18 to 49 years of age and of adults with chronic diseases: adjuvanted sub-unit herpes zoster vaccine]; [cited 2020 Nov 16]. Available from: https:\/\/www.inspq.qc.ca\/publications\/2705"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2021.1956906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T07:20:39Z","timestamp":1650525639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2021.1956906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,2]]}},"alternative-id":["10.1080\/14760584.2021.1956906"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2021.1956906","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}